Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1692-1698

  Rossi, Antonio ^a   Di Maio, Massimo ^b   Chiodini, Paolo ^c   Rudd, Robin Michael ^e   Okamoto, Hiroaki ^h   Skarlos, Dimosthenis Vasilios ^k   Früh, Martin ^m   Qian, Wendi ^f   Tamura, Tomohide ⁱ   Samantas, Epaminondas ^l   Shibata, Taro ^j   Perrone, Francesco ^b   Gallo, Ciro ^c   Gridelli, Cesare ^a   Martelli, Olga ^d   Lee, Siow Ming ^g  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^e London Lung Cancer Group   (United Kingdom)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^j NATIONAL CANCER CENTER   (Japan)

^k Metropolitan Hospital   (Greece)

^l Oncological Hospital Agioi Anargiroi   (Greece)

^m CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; LOMUSTINE; METHOTREXATE; TENIPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; HAZARD RATIO; HUMAN; LEUKOPENIA; LOG RANK TEST; LUNG SMALL CELL CANCER; MANTEL HAENSZEL TEST; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; STRATIFIED SAMPLE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; ADULT; AGED; CANCER INVASION; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; ITALY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863752868     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.4905     Document Type: Article

References (29)

1. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24:4539-4544, 2006
2. Simon GR, Turrisi A, American College of Chest Physicians: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:324S-339S, 2007 (suppl 3)
3. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer - Version v2.2012. http://www.nccn.org
4. Stahel R, Thatcher N, Früh M, et al: 1st ESMO Consensus Conference in lung cancer: Lugano 2010 - Small-cell lung cancer. Ann Oncol 22:1973-1980, 2011
5. Johnson SW, O'Dwyer PJ: Pharmacology of cancer chemotherapy: Cisplatin and its analogues, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 7). Philadelphia, PA, Lippincott Williams and Wilkins, 2005 pp 344-358
6. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999
7. du Bois A, Lück HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329, 2003
8. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
9. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9:13-21, 1998
10. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007
11. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004
12. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2:475-482, 2001
13. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
14. Smith CT, Williamson PR, Marson AG: Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 24:1307-1319, 2005
15. Reis IM, Hirji KF, Afifi AA: Exact and asymptotic tests for homogeneity in several 2 x 2 tables. Stat Med 18:893-906, 1999
16. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study - Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21:23-30, 1994
17. Steele JP: Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: A phase III randomized trial with quality-of-life evaluation. Semin Oncol 28:15-18, 2001
18. Kumagai M, Kutsuzawa T, Fuyuno G, et al: Comparison of carboplatin/etoposide/vincristine with cisplatin/etoposide as combination chemotherapy for small cell lung cancer. Tokaj J Exp Clin Med 20:209-214, 1995
19. Socinski MA, Weissman C, Hart LL, et al: Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840-4847, 2006
20. Monnet I, Chariot P, Quoix E, et al: Extensive small-cell lung cancer: A randomized comparison of two chemotherapy programs with early crossover in instance of failure - Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT). Ann Oncol 3:813-817, 1992
21. Joss RA, Alberto P, Hürny C, et al: Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 6:41-48, 1995
22. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601-607, 1994
23. Okamoto H, Watanabe K, Kunikane H, et al: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97:162-169, 2007
24. Lee SM, James LE, Qian W, et al: Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 64:75-80, 2009
25. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors - Version v1.2011. http://www.nccn.org
26. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer- and chemotherapy-induced anemia - Version v2.2012. http://www.nccn.org
27. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Antiemesis - Version v1.2012. http://www.nccn.org
28. Rossi A, Di Maio M, Martelli O, et al: Cisplatin versus carboplatin-based regimens in the treatment of small cell lung cancer (SCLC): Meta-analysis of published randomized clinical trials (RCTs). J Thorac Oncol 4:S397-S398, 2009 (suppl 1; abstr D6.3)
29. Piedbois P, Buyse M: Meta-analyses based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 22:3839-3841, 2004